Bi-specific CAR-iNKT cell immunotherapy for high-risk KMT2A-rearranged leukemia outperforms CAR-T in an NKG2D-dependent manner and eradicates leptomeningeal disease
Hongwei Ren, Natalina Elliott, Bryan Lye, Mohammad Umer Sharif Shohan, Joe W. Cross, Lucy May Field, Kanagaraju Ponnusamy, Siobhan Rice, Thomas Jackson, Ilia Leontari, Nouhad El Ouazzani, Rebecca Thomas, Sarah Inglott, Jack Luke Bartram, Owen Patrick Smith, , Anastasios Karadimitris
This paper develops bi-specific CAR-iNKT cells targeting CD19 and CD133 for KMT2A-rearranged leukemia, showing superior efficacy over CAR-T in eradicating leptomeningeal disease and inducing remission.
bioRxiv · Jan 22, 2025 · PreprintCancer Biology